Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaMonika Brüggemann, Michael Kneba, Makoto Nakao et al.|Blood|2005Cited by 537
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLCGilberto de Castro, Tony Mok, Naiyer A. Rizvi et al.|Journal of Thoracic Oncology|2022Cited by 72
GliPR1 knockdown by RNA interference exerts anti‐glioma effects in vitro and in vivoUrban Scheuring, Stefanie Tietze|Journal of Neuro-Oncology|2021Cited by 9